ArticleExperimental and therapeutic medicine2026
Impact of vitamin D receptor gene variants on psoriasis vulgaris susceptibility and clinical phenotype in a Greek population.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis vulgaris (PsV) is a complex immune-mediated disease with a polygenic component. Common variants in the vitamin D receptor (VDR) gene have been explored in the context of psoriasis, but findings remain inconsistent and data from the Greek population are scarce. Thus, the present study aimed to investigate the association of the VDR FokI (rs2228570), BsmI (rs1544410) and TaqI (rs731236) single-nucleotide polymorphisms (SNPs) with PsV susceptibility and clinical phenotype in a Caucasian Greek cohort. In this observational cross-sectional study, 203 patients with chronic plaque psoriasis and 812 age-, sex- and ethnically-matched controls of Greek origin were genotyped for the selected VDR SNPs using real-time PCR (melting curve analysis) and SNP-based statistical comparisons were performed. Case-control analyses exhibited a significant association between the BsmI variant and PsV susceptibility under the recessive and allelic models, with the A allele (A vs. G; OR: 0.765; 95% CI: 0.614-0.953; adjusted P=0.032) and AA genotype (AA vs. GA + GG; OR: 0.577; 95% CI: 0.386-0.861; adjusted P=0.028) conferring a protective effect. No impact on PsV risk was observed for FokI or TaqI. Intra-patient subgroup analyses based on clinical traits indicated phenotype-specific contributions: FokI was associated with early-onset and familial disease, TaqI with psoriatic arthritis and both BsmI and TaqI with nail involvement. To the best of our knowledge, this study provides the first evidence that VDR genetic variation may influence PsV susceptibility and clinical expression in the Greek population. The VDR locus could thus serve as a potential biomarker for tailored risk stratification and clinical profiling in PsV. Further large-scale studies integrating genotypic and phenotypic data, especially among Caucasians, are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.